Clarity Alzheimer's Disease Study
Researchers at SymmetryScience Group, Inc. are partnering with individuals diagnosed with mild Alzheimer's disease to evaluate how an investigational virtual reality headset can help. Join our compensated study today.
Fast Facts
diagnosed with mild alzheimer's disease
50-90 years old
Compensation Provided
Conducted in Scranton, PA
Study Background
Our researchers invite you to join the Clarity Alzheimer’s Disease Study (CAD). In this study, we’re examining the use of an investigational, non-invasive virtual reality (VR) headset for individuals with Alzheimer’s. We want to see if stimulating the eyes and ears with the headset can effectively change brain activity.
Participation will include a number of intake activities before the study, as well as two days of experimental sessions with the VR headset. If you have been diagnosed with mild Alzheimer’s disease, you may be eligible to enroll.
Your participation in this study may help researchers improve treatment approaches for Alzheimer’s disease. Help us advance research today!
Study Background
Our researchers invite you to join the Clarity Alzheimer’s Disease Study (CAD). In this study, we’re examining the use of an investigational, non-invasive virtual reality (VR) headset for individuals with Alzheimer’s. We want to see if stimulating the eyes and ears with the headset can effectively change brain activity.
Participation will include a number of intake activities before the study, as well as two days of experimental sessions with the VR headset. If you have been diagnosed with mild Alzheimer’s disease, with a MoCA score of 18-25, you may be eligible to enroll.
Your participation in this study may help researchers improve treatment approaches for Alzheimer’s disease. Help us advance research today!
Additional Information
You may qualify for this study if you meet the following criteria.
Inclusion Criteria:
- 50-90 years old
- Diagnosis of mild Alzheimer’s disease
- Willing to sign informed consent document
- If you do not have the capacity to sign the informed consent, a legally authorized representative will be asked to provide surrogate consent.
- Willing to wear a watch-like device on the dominant wrist during study period
- Willing to do a blood draw
- Normal or corrected to normal vision
- Normal hearing
- Fluent in English
Exclusion Criteria:
- Taking a stable dose of acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine and galantamine), Nmethyl-D-aspartate (NMDA) receptor antagonists (e.g., memantine), or monoclonal antibody medication
- History of seizure or epilepsy, including family history of seizure or epilepsy
- History of stroke
- History of narrow angle (acute angle) glaucoma
- Diagnosis of migraine headache
- History of alcohol use disorder within the past 2 years
- Current or past history of any neurological disorder other than dementia
- Use of hearing aid device(s)
- Any known blood pathogens or disorders
- Any clinically significant medical disorder, condition, disease, or clinically significant finding at screening that precludes your participation in study activities
- Pregnancy
Before the study begins, potential participants will complete the following intake activities:
- Written Informed consent (or legally authorized representative consent with participant assent, as applicable)
- Demographics (includes race, ethnicity, medical history, education level, and gender)
- Current Medication/Medication History
- Brief cognitive assessment
- Hearing and Vision tests
- Brief word reading assessment
- Inclusion/exclusion criterion validation
- Assessment to determine dominant hand
- Questionnaire to determine emotional state
- Blood Draw
Participants will then complete 2 days of experimental sessions. Each day will include:
- Experimental VR headset session
- Questionnaire
Finally, participants will wear a watch-like device in between the two experimental days.
